Search

Only show content I have access to (0)

Chapters (1)

Over 3 years (1)

From year:

To year:

Apply

Medicine (1)

Cambridge University Press (1)

1 results

19 - Urinary retention
from Section 3 - Specific conditions
- By Jalesh N. Panicker, Ranan DasGupta, Sohier Elneil, Clare J. Fowler
Edited by Clare J. Fowler, Jalesh N. Panicker, Anton Emmanuel, University College London
Book:

Pelvic Organ Dysfunction in Neurological Disease

Published online:

06 December 2010

Print publication:

04 November 2010, pp 293-306
- Chapter
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation
Summary

Sexual function is recognized as an important factor determining quality of life and dysfunction in neurological patients may significantly add to the burden of their disease. Any disruption in the sexual response cycle results in sexual dysfunction (SD). Laboratory testing should be tailored according to patient symptoms and risk factors. Fasting glucose and lipid profile may be measured to assess atherosclerotic risk factors for erectile dysfunction (ED). Oral drugs should be considered as first-line therapy for neurogenic ED. There are fewer evidence-based therapeutic options for treatment of female SD. However it is an area of increasing interest and marketing of therapies by pharmaceutical companies. Therapies relate to treatment of sexual desire, arousal, orgasm and/or sexual pain. The term hypoactive sexual desire disorder (HSDD) is used to describe low sexual desire and distress, and many therapies aim to address this aspect of female sexual function.